| Tagrisso (osimertinib) / AstraZeneca |
| Active, not recruiting | 3 | 419 | Europe, Canada, Japan, US, RoW | Chemotherapy, Osimertinib, Platinum-based Doublet-Chemotherapy, Cross-over to Osimertinib | AstraZeneca | Anticancer Treatment | 04/16 | 12/23 | | |
|
|
|
|
| Active, not recruiting | 3 | 674 | Europe, Canada, Japan, US, RoW | AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Tarceva 150/100 mg, Placebo Gefitinib 250 mg, Placebo Iressa 250 mg, Erlotinib 150/100 mg, Tarceva 150/100 mg, Gefitinib 250 mg, Iressa 250mg, Placebo AZD9291 80 mg/ 40 mg | AstraZeneca, Parexel | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer | 06/17 | 01/25 | | |
|
|
|
|
|
|
|
CAURAL, NCT02454933: Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours |
|
|
| Completed | 3 | 29 | Canada, RoW | AZD9291, MEDI4736 | AstraZeneca | Locally Advanced or Metastatic EGFR T790M+ NSCLC | 08/17 | 06/23 | | |
|
|
| Completed | 3 | 256 | RoW | T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG, Visual Slit-Lamp Testing, AZD9291 Dosing, Plasma AZD9291 testing | AstraZeneca, TigerMed | Lung Cancer | 10/18 | 10/18 | | |
RELAY, NCT02411448 / 2014-004824-22: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC |
|
|
| Active, not recruiting | 3 | 545 | Europe, Canada, Japan, US, RoW | Ramucirumab, LY3009806, Placebo, Erlotinib, Gefitinib, Osimertinib | Eli Lilly and Company | Metastatic Non-Small Cell Lung Cancer | 01/19 | 12/24 | | |
|
|
|
|
| Completed | 3 | 3017 | Europe, Canada, RoW | T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG, Visual Slit-Lamp Testing, AZD9291 Dosing | AstraZeneca, Parexel | Lung Cancer | 04/19 | 04/19 | | |
APOLLO, NCT02972333: Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M |
|
|
| Unknown status | 3 | 150 | NA | AZD9291 80mg oral each day, AZD9291, 80mg, QD, p.o. (2nd line or later), Radiation therapy, WBRT or SRS | Shandong Cancer Hospital and Institute, AstraZeneca | EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases | 09/19 | 12/19 | | |
ADAURA, NCT02511106 / 2015-000662-65: AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. |
|
|
| Active, not recruiting | 3 | 682 | Europe, Canada, Japan, US, RoW | AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg | AstraZeneca | Stage IB-IIIA Non-small Cell Lung Carcinoma | 04/22 | 01/29 | | |
|
|
|
|
|
|
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC) |
|
|
| Not yet recruiting | 3 | 204 | Europe | Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04] | | | | |
2021-001825-33: A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure |
|
|
| Not yet recruiting | 3 | 690 | Europe, RoW | Amivantamab, Lazertinib, JNJ-61186372, JNJ-73841937/YH-25448, Solution for infusion, Tablet | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research and Development, Janssen Cilag SpA | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, A specific type of lung cancer called "Non-Small Cell Lung Cancer", Diseases [C] - Cancer [C04] | | | | |
2021-004135-89: A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small cell lung cancer, following complete tumour resection. Ensayo clínico para investigar la eficacia y seguridad de Osimertinib versus Placebo en pacientes en estadío IA2-IA3 de cáncer de pulmón no microcítico, tras la resección completa del tumor. |
|
|
| Not yet recruiting | 3 | 380 | Europe | Osimertinib 40 mg, Osimertinib 80 mg, AZD9291, Film-coated tablet, Tagrisso | AstraZeneca AB, ASTRAZENECA AB, AstraZenecaAB | Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection. Estadio IA2-IA3 de cáncer de pulmón no microcítico, positivo para la mutación de EGFR (Ex19del, L858R), tras la resección completa del tumor., Specific type of lung cancer called non-small cell lung cancer (NSCLC) stage IA2-IA3 with EGFR mutations positive after complete surgical removal of a tumour between 1 and 3 centimetres. Tipo específico de cáncer de pulmón no microcítico (CPNM) en estadío IA2-IA3 positivo para mutaciones de EGFR, tras la resección completa del tumor entre 1 y 3 centímetros., Diseases [C] - Cancer [C04] | | | | |
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico |
|
|
| Not yet recruiting | 3 | 324 | Europe | Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04] | | | | |
2022-000525-25: A Clinical Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy Uno studio clinico di lazertinib con amivantamab per via sottocutanea somministrato tramite iniezione manuale rispetto ad amivantamab per via endovenosa o ad amivantamab per via sottocutanea in pazienti con carcinoma polmonare non a piccole cellule avanzato o metastatico con mutazioni di EGFR dopo progressione durante il trattamento con osimertinib e chemioterapia |
|
|
| Ongoing | 3 | 640 | Europe | Amivantamab (JNJ-61186372), Amivantamab (JNJ-61186372) co-formulated with recombinant human hyaluronidase (rHuPH20), Amivantamab JNJ-61186372 co-formulated with recombinant human hyaluronidase (rHuPH20) OBDS, Lazertinib mesylate monohydrate, [JNJ-61186372], [JNJ-73841937-ZCY/YH25448AM], Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Film-coated tablet | JANSSEN CILAG INTERNATIONAL NV, Janssen-Cilag International NV, Janssen Research & Development, LLC | EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer carcinoma polmonare non a piccole cellule avanzato o metastatico con mutazioni di EGFR, A specific type of lung cancer called "Non-Small Cell Lung Cancer" carcinoma polmonare non a piccole cellule, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 3 | 6 | Japan, RoW | Capmatinib, INC280, Osimertinib, Pemetrexed, Cisplatin, Carboplatin | Novartis Pharmaceuticals | Carcinoma, Non-Small-Cell Lung | 12/22 | 12/22 | | |
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 587 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin | AstraZeneca | Non-Small Cell Lung Cancer | 04/23 | 06/26 | | |
|
|
MARIPOSA-2, NCT04988295: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure |
|
|
| Active, not recruiting | 3 | 776 | Europe, Canada, Japan, US, RoW | Lazertinib, JNJ-73841937, YH-25448, Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 07/23 | 12/25 | | |
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer |
|
|
| Terminated | 3 | 8 | US | Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar | EQRx International, Inc. | NSCLC | 08/23 | 08/23 | | |
PALOMA-3, NCT05388669 / 2022-000525-25: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 418 | Europe, Canada, Japan, US, RoW | Lazertinib, JNJ-73841937, YH25448, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), JNJ-61186372, Amivantamab Intravenous | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Advanced or Metastatic Non-small Cell Lung Cancer | 01/24 | 01/25 | | |
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 216 | Europe, Japan, US, RoW | Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg | AstraZeneca | Non Small Cell Lung Cancer (Stage III) | 01/24 | 06/26 | | |
|
|
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations |
|
|
| Not yet recruiting | 3 | 398 | NA | JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC | 03/27 | 03/28 | | |
TROPION-Lung14, NCT06350097: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 582 | Europe, RoW | Osimertinib, Osimertinib: AZD9291, Datopotamab Deruxtecan: Dato-DXd, Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | Non-small Cell Lung Cancer | 03/28 | 05/32 | | |
| Active, not recruiting | 3 | 1074 | Europe, Canada, Japan, US, RoW | Amivantamab, JNJ-61186372, Osimertinib, Lazertinib, JNJ-73841937 and YH-25448, Placebo | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 04/24 | 06/27 | | |
|
COMPEL, NCT04765059: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 98 | Europe, US, RoW | Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin | AstraZeneca, Parexel | Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
NeoADAURA, NCT04351555 / 2020-000058-89: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 328 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291; TAGRISSO, Cisplatin, Carboplatin, Placebo, Pemetrexed | AstraZeneca | Non-Small Cell Lung Cancer | 07/24 | 06/29 | | |
|
TROPION Lung15, NCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 630 | NA | Dato-DXd, DS-1062a, Osimertinib, Tagrisso, AZD9291, Pemetrexed, Carboplatin, Cisplatin | AstraZeneca, Daiichi Sankyo | Metastatic Non-small Cell Lung Cancer | 09/26 | 02/28 | | |
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification |
|
|
| Recruiting | 3 | 250 | RoW | Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin | Hutchison Medipharma Limited | Non-small Cell Lung Cancer | 09/24 | 11/24 | | |
SANOVO, NCT05009836: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 3 | 320 | RoW | Savolitinib, HMPL-504, Placebo | Hutchison Medipharma Limited | Non-small Cell Lung Cancer | 11/24 | 01/25 | | |
ROSY-T, NCT05629234: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) |
|
|
| Active, not recruiting | 3 | 37 | Europe, RoW | Osimertinib, TAGRISSO | AstraZeneca, Parexel | Cancer | 02/25 | 02/25 | | |
FLETEO, NCT05382728: Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 680 | RoW | TY-9591, TY-9591 Tablets, placebo Osimertinib, placebo Tagrisso, Osimertinib, Tagrisso, placebo TY-9591, placebo TY-9591 Tablets | TYK Medicines, Inc | NSCLC, EGFR Activating Mutation | 05/25 | 12/27 | | |
SAFFRON, NCT05261399: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment |
|
|
| Recruiting | 3 | 324 | Europe, Canada, Japan, US, RoW | Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 06/25 | 12/26 | | |
PACIFIC-4, NCT03833154 / 2018-002572-41: Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation |
|
|
| Recruiting | 3 | 690 | Europe, Canada, Japan, US, RoW | Durvalumab, MEDI4736, Placebo, Osimertinib (single-arm, open-label) | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 03/26 | 04/28 | | |
|
|
ADAURA2, NCT05120349: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection |
|
|
| Recruiting | 3 | 380 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291; TAGRISSO, Placebo | AstraZeneca | Non-Small Cell Lung Cancer | 08/27 | 11/32 | | |
M22-142, NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein |
|
|
| Withdrawn | 3 | 250 | NA | Telisotuzumab Vedotin, ABBV-399, Osimertinib, Cisplatin, Carboplatin, Pemetrexed | AbbVie | Non-Small Cell Lung Cancer | 04/28 | 04/28 | | |
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. |
|
|
| Recruiting | 2/3 | 14 | RoW | SI-B001, Osimertinib | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 08/24 | 08/24 | | |
